


HSL

# NEURO PHARMACOLOGY



LOCALIZATION & EXPRESSION OF HmGluR1

HEALTH SCIENCES LIBRARY  
University of Wisconsin

MAR 14 1997

1005 Linden Drive  
Madison, WI 53706

INES  
RS

## NEUROPHARMACOLOGY

## Chief Editor

GRAHAM L. COLLINGRIDGE

## Editorial Assistant

ELIZABETH J. COAN

## Neuropharmacology

Editorial Office

University of Bristol  
Bristol BS8 1TH, U.K.

## Executive Editorial Board

NICHOLAS M. BARNES, Birmingham  
JOËL G. BOCKAERT, Montpellier  
RAYMOND J. DINGLEDINE, Atlanta  
JOHN GARTHWAITE, London  
A. RICHARD GREEN, Loughborough  
DAVID LODGE, London  
ROBERT L. MACDONALD, Ann Arbor

IAN L. MARTIN, Edmonton  
RICHARD J. MILLER, Chicago  
MASAYOSHI MISHINA, Tokyo  
PETER H. SEEBURG, Heidelberg  
MICHAEL A. SIMMONDS, London  
DAVID N. STEPHENS, Brighton  
MICHAEL A. ROGAWSKI, Bethesda

## Editors Emeriti

PHILIP B. BRADLEY, Birmingham  
ERMINIO COSTA, Washington, D.C.

## Advisory Editorial Board

SIMON ALFORD, Chicago  
PHILIPPE ASCHER, Paris  
BRIAN AULT, Radnor  
BRUCE P. BEAN, Boston  
TIM BLISS, London  
NORMAN G. BOWERY, Birmingham  
GODFREY G. S. COLLINS, Sheffield  
ALAN J. CROSS, Rochester, NY  
COLIN T. DOURISH, Maidenhead  
ANDREW DRAY, Laval, Canada  
RICHARD H. EVANS, Bristol  
BERTIL B. I. FREDHOLM, Stockholm  
ANN G. HAYES, Ware  
P. MAX HEADLEY, Bristol  
DAVID J. HEAL, Nottingham  
GRAEME HENDERSON, Bristol  
RAY G. HILL, Harlow

TAGE HONORÉ, Basel  
DANIEL HOYER, Basel  
SUSAN D. IVERSEN, Oxford  
DAVID J. JULIUS, San Francisco  
GAVIN J. KILPATRICK, Basel  
ARTHUR KONNERTH, Homburg  
JEREMY J. LAMBERT, Dundee  
ROBIN A. J.-LESTER, Birmingham, AL  
HILARY J. LITTLE, Durham  
ROBERT C. MALENKA, San Francisco  
CHARLES A. MARSDEN, Nottingham  
MARK L. MAYER, Bethesda  
JAMES O. MCNAMARA, Durham  
BRIAN S. MELDRUM, London  
HANNAH MONYER, Heidelberg  
RICHARD G. M. MORRIS, Edinburgh  
DAVID B. MORTON, Birmingham

STEFAN R. NAHORSKI, Leicester  
SHIGETADA NAKANISHI, Kyoto  
GIUSEPPE NISTICÒ, Rome  
STEVEN M. PAUL, Indianapolis  
TERRY D. REISINE, Philadelphia  
KLAUS G. REYMANN, Magdeburg  
JOHN RODGERS, Leeds  
NANCY J. ROTHWELL, Manchester  
TREVOR SHARP, Oxford  
TREVOR G. SMART, London  
IAN P. STOLERMAN, London  
RICHARD W. TSIEN, Stanford  
JOHN L. WADDINGTON, Dublin  
JEFFREY C. WATKINS, Bristol  
MICHAEL M. WHITE, Philadelphia  
ADRIAN C. WILLIAMS, Birmingham

*Publishing Office.* Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, U.K.

*Production Editors:* Caroline Cowan and Emma Hollingsworth.

*Advertising Office:* Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, U.K. (Tel. Oxford (01865) 843000; Fax (01865) 843010).

Copyright © 1997 Elsevier Science Ltd. All rights reserved

Annual Institutional Subscription Rates 1997: Europe, The CIS and Japan 2743 Dutch Guilders. All other countries US\$1693. Associated Personal Subscription rates are available on request for those whose institutions are library subscribers. Dutch Guilder prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice.

For orders, claims, product enquiries (no manuscript enquiries) please contact the Customer Support Department at the Regional Sales Office nearest to you:

**The Americas:** Elsevier Science Customer Support Department, P.O. Box 945, New York, NY 10010, USA [Tel: (+1) 212-633-3730/1-888 4ES-INFO. Fax: (+1) 212-633-3680. E-mail: [usinfo-f@elsevier.com](mailto:usinfo-f@elsevier.com)].

**Japan:** Elsevier Science Customer Support Department, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan [Tel: (+3) 5561-5033. Fax: (+3) 5561-5047. E-mail: [kyf04035@niftyserve.or.jp](mailto:kyf04035@niftyserve.or.jp)].

**Asia Pacific (excluding Japan):** Elsevier Science (Singapore) Pte Ltd, No. 1 Temasek Avenue, 17-01 Millenia Tower, Singapore 039192 [Tel: (+65) 434-3727. Fax: (+65) 337-2230. E-mail: [asiainfo@elsevier.com.sg](mailto:asiainfo@elsevier.com.sg)].

**Rest of the World:** Elsevier Science Customer Service Department, P.O. Box 211, 1001 AE Amsterdam, The Netherlands [Tel: (+31) 20-485-3757. Fax: (+31) 20-485-3432. E-mail: [nlinfo-f@elsevier.nl](mailto:nlinfo-f@elsevier.nl)].

Periodicals postage paid at Rahway, NJ. Neuropharmacology (ISSN 0028-3908) is published monthly by Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, U.K. The annual subscription in the U.S.A. is \$1693. Neuropharmacology is distributed by Mercury Airfreight International Ltd, 10 Camptown Road, Irvington, NJ 07111-1105. Postmaster: please send address corrections to Neuropharmacology, c/o Elsevier Science RSO, Customer Support Department, 655 Avenue of the Americas, New York, NY 10010, USA [Tel: (+1) 212-633-3730/1-888 4ES-INFO. Fax: (+1) 212-633-3680. E-mail: [usinfo-f@elsevier.com](mailto:usinfo-f@elsevier.com)].

*Cover*—Structural model of the core portion of a Shaker potassium channel view down the axis of the pore from outside the cell. The channel has four identical subunits. The backbone of each subunit is colored according to the spectrum beginning with the N-terminal of S5 in red and ending at prolines in S6 in blue. The P or H5 region that forms the ion selective portion of the pore is postulated to span the outer half of the transmembrane region and be formed by an alpha helix (green) followed by an extended coil structure (cyan). Model by Guy, H.R. and Durell, S.R. (1996) *Biophysical J. Abstracts*.

## CONTENTS

D. Stephan, C. Bon, J. A. Holzwarth, M. Galvan and R. M. Pruss	Human metabotropic glutamate receptor 1: mRNA distribution, chromosome localization and functional expression of two splice variants	1649
D. D. Schoepp, C. R. Salhoff, R. A. Wright, B. G. Johnson, J. P. Burnett, N. G. Mayne, R. Belagaje, S. Wu and J. A. Monn	The novel metabotropic glutamate receptor agonist 2R,4R-APDC potentiates stimulation of phosphoinositide hydrolysis in the rat hippocampus by 3,5-dihydroxyphenylglycine: evidence for a synergistic interaction between group 1 and group 2 receptors	1661
A. E. King and X. H. Liu	Dual action of metabotropic glutamate receptor agonists on neuronal excitability and synaptic transmission in spinal ventral horn neurons <i>in vitro</i>	1673
D. Lodge, A. Bond, M. J. O'Neill, C. A. Hicks and M. G. Jones	Stereoselective effects of 2,3-benzodiazepines <i>in vivo</i> : electrophysiology and neuroprotection studies	1681
D. Bleakman, B. A. Ballyk, D. D. Schoepp, A. J. Palmer, C. P. Bath, E. F. Sharpe, M. L. Woolley, H. R. Bufton, R. K. Kamboj, I. Tarnawa and D. Lodge	Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors <i>in vitro</i> : stereospecificity and selectivity profiles	1689
A. Boireau, F. Bordier, G. Durand and A. Doble	The antidepressant metapramine is a low-affinity antagonist at <i>N</i> -methyl-D-aspartic acid receptors <sub>1</sub>	1703
K. A. Grant, G. Colombo, J. Grant and M. A. Rogawski	Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists	1709
C. N. Hinko, A. M. Crider, M. A. Kliem, C. L. Steinmiller, T. H. Seo, Bin Ho, P. Venkatarangan, A. A. El-Assadi, Hyejung Chang, C. M. Burns, E. I. Tietz, P. H. Andersen and H. Klitgaard	Anticonvulsant activity of novel derivatives of 2- and 3-piperidinecarboxylic acid in mice and rats	1721
J. Kriegelstein, K. Lippert and G. Pöch	Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage	1737
J. Gleitz, C. Tosch, A. Beile and T. Peters	The protective action of tetrodotoxin and ( $\pm$ )-kavain on anaerobic glycolysis, ATP content and intracellular Na <sup>+</sup> and Ca <sup>2+</sup> of anoxic brain vesicles	1743
E. Sanna, A. Murgia, A. Casula, M. Usala, E. Maciocco, G. Tuligi and G. Biggio	Direct activation of GABA <sub>A</sub> receptors by loreclezole, an anticonvulsant drug with selectivity for the $\beta$ -subunit	1753
M. D. Vaughn, M. F. Pozza and K. Lingenhöhl	Excitatory acoustic responses in the inferior colliculus of the rat are increased by GABA <sub>B</sub> receptor blockade	1761
B. Lendvai, H. Sershen, A. Lajtha, E. Santha, M. Baranyi and E. S. Vizi	Differential mechanisms involved in the effect of nicotinic agonists DMPP and lobeline to release [ <sup>3</sup> H]5-HT from rat hippocampal slices	1769
S. M. Pearl, I. M. Maisonneuve and S. D. Glick	Prior morphine exposure enhances ibogaine antagonism of morphine-induced dopamine release in rats	1779
E. Meller and K. Bohmaker	Chronic treatment with antipsychotic drugs does not alter G protein $\alpha$ or $\beta$ subunit levels in rat brain	1785
J. L. Wiley, D. R. Compton, P. M. Gordon, C. Siegel, M. Singer, A. Dutta, A. H. Lichtman, R. L. Balster, R. K. Razdan and B. R. Martin	Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of $\Delta^8$ -tetrahydrocannabinol	1793
P. Deval, V. Lenoir, C. Garret and B. Kerdelhue	Reduction of the amplitude of preovulatory LH and FSH surges and of the amplitude of the <i>in vitro</i> GnRH-induced LH release by Substance P. Reversal of the effect by RP 67580	1805
<i>Rapid Communication</i>		
L. Pulvirenti, C. Balducci and G. F. Koob	Inhibition of nitric oxide synthesis reduces intravenous cocaine self-administration in the rat	1811
	Book reviews	1815
	Announcement	1819
	Contents List, Author and Subject Index, Volume 35 (1996)	I

*Neuropharmacology* is Indexed/Abstracted in BIOSIS Data., Chem. Abstr. Serv., Curr. Cont./Life Sci., CABS, Excerpt. Med., Curr. Cont. ISI/BIOMED. Data., MEDLINE, PASCAL-CNRS Data., Psychol. Abstr., Res. Alert, Curr. Cont. Sci. Cit. Indx, Curr. Cont. SCISEARCH Data., Indx Med.



PERGAMON



ISSN 0028-3908  
NEPHBW 35(12) 1649-1820 (1996)



Pergamon

PII: S0028-3908(96)00105-0

*Neuropharmacology*, Vol. 35, No. 12, pp. 1721–1735, 1996  
Copyright © 1997 Elsevier Science Ltd. All rights reserved  
Printed in Great Britain  
0028-3908/96 \$15.00 + 0.00

## Anticonvulsant Activity of Novel Derivatives of 2- and 3-Piperidinecarboxylic Acid in Mice and Rats

C. N. HINKO<sup>1\*</sup>, A. M. CRIDER<sup>2</sup>, M. A. KLIEM<sup>1</sup>, C. L. STEINMILLER<sup>1</sup>, T. H. SEO<sup>1</sup>, BIN HO<sup>2</sup>,  
P. VENKATARAMAN<sup>2</sup>, A. A. EL-ASSADI<sup>1</sup>, HYEJUNG CHANG<sup>1</sup>, C. M. BURNS<sup>1</sup>,  
E. I. TIETZ<sup>3</sup>, P. H. ANDERSEN<sup>4</sup> and H. KLITGAARD<sup>4</sup>

<sup>1</sup>College of Pharmacy, The University of Toledo, Toledo, OH 43606, U.S.A.; <sup>2</sup>School of Pharmacy, Northeast Louisiana University, Monroe, LA 71209, U.S.A.; <sup>3</sup>Department of Pharmacology, Medical College of Ohio, Toledo, OH 43699, U.S.A.; <sup>4</sup>Novo Nordisk A/S, Bagsvaerd, Denmark

(Accepted 28 June 1996)

**Summary**—The relative ability of derivatives of 2-piperidinecarboxylic acid (2-PC; pipecolic acid) and 3-piperidinecarboxylic acid (3-PC; nipecotic acid) to block maximal electroshock (MES)-induced seizures, elevate the threshold for electroshock-induced seizures and be neurotoxic in mice was investigated. Protective index (PI) values, based on the MES test and rotorod performance, ranged from 1.3 to 4.5 for 2-PC benzylamides and from <1 to >7.2 for 3-PC derivatives. PI values based on elevation of threshold for electroshock-induced seizures and rotorod performance ranged from >1.6 to >20 for both types of derivatives. Since preliminary data indicated that benzylamide derivatives of 2-PC displace [<sup>3</sup>H]1-[1-(2-thienyl)-cyclohexyl]piperidine (TCP) binding to the phencyclidine (PCP) site of the *N*-methyl-D-aspartate (NMDA) receptor in the micromolar range and such low affinity uncompetitive antagonists of the NMDA receptor-associated ionophore have been shown to be effective anticonvulsants with low neurological toxicity, the 2-PC derivatives were evaluated in rat brain homogenates for binding affinity to the PCP site. Although all compounds inhibited [<sup>3</sup>H]TCP binding, a clear correlation between pharmacological activity and binding affinity was not apparent. Select compounds demonstrated minimal ability to protect against pentylene-tetrazol-, 4-aminopyridine- and NMDA-induced seizures in mice. Corneal and amygdala kindled rats exhibited different sensitivities to both valproic acid and the nonsubstituted 2-PC benzylamide, suggesting a difference in these two models. Enantiomers of the  $\alpha$ -methyl substituted benzylamide of 2-PC showed some ability to reduce seizure severity in amygdala kindled rats. © 1997 Elsevier Science Ltd. All rights reserved.

**Keywords**—2-piperidinecarboxylic acid, 3-piperidinecarboxylic acid, corneal kindling, amygdala kindling, uncompetitive NMDA antagonists, anticonvulsant.

Prior studies have shown that derivatives of 3-piperidinecarboxylic acid (3-PC or nipecotic acid) provide protection against chemically induced seizures (Crider *et al.*, 1982, 1984; Hinko *et al.*, 1984, 1988, 1992). Nipecotic acid is one of the most potent inhibitors of gamma-aminobutyric acid (GABA) uptake into rat cerebral cortex (Krogsgaard-Larsen and Johnston, 1975) and mouse whole brain mini-slices (Wood *et al.*, 1979). Both alkyl and phenyl esters of nipecotic acid have varying degrees of ability to inhibit GABA uptake into whole mouse brain mini-slices (Hinko *et al.*, 1988). Presumably the anticonvulsant activity of these nipecotic acid

prodrugs results, at least in part, from a GABA-mimetic action.

Previous reports have also demonstrated that 2-piperidinecarboxylic acid (2-PC or pipecolic acid), a metabolite of the amino acid lysine, reduces synaptosomal and glial uptake of GABA in rat brain (Nomura *et al.*, 1981). L-Pipecolic acid, when administered by intraperitoneal (i.p.) injection, significantly increases the onset of clonic and tonic seizures induced by pentylene-tetrazol in mice (Chang *et al.*, 1988). Kohn *et al.* (1990, 1991, 1993) have reported that benzylamide derivatives of amino acids provide excellent protection against maximal electroshock (MES) seizures in mice, although a mechanism for these compounds has not been proposed. In preliminary testing done in this laboratory, benzylamides of pipecolic acid demonstrate anticonvulsant


\*To whom correspondence should be addressed.

activity against MES seizures. Receptor binding studies indicated that the benzylamides displace [ $^3\text{H}$ ]1-[1-(2-thienyl)cyclohexyl]piperidine (TCP) binding to the phencyclidine (PCP) site of the *N*-methyl-D-aspartate (NMDA) receptor in the micromolar range. The latter finding suggests that these derivatives may be functioning as low-affinity, uncompetitive NMDA antagonists (Hinko *et al.*, 1994).


High-affinity uncompetitive antagonists of the NMDA receptor-associated ionophore, such as PCP and dizocilpine (MK-801), are highly effective as anticonvulsant agents (Leander *et al.*, 1988; Chapman and Meldrum, 1989). Unfortunately, they produce significant neurotoxicity, with i.p. protective index (PI) values with respect to motor impairment in mice of less than one. It is unlikely, therefore, that they will be useful clinically in the treatment of epilepsy. Recently, it has been suggested that low-affinity uncompetitive antagonists, such as phencyclohexylamine (PCA) and 5-aminocarbonyl-10,11-dihydro-5*H*-dibenzo[*a,d*]cyclohepten-5,10-imine (ADCI), are effective anticonvulsants with low neurological toxicity and i.p. PI values in the range of 3–4. The affinity of these analogs for the PCP site of the NMDA receptor is in the low-micromolar range, whereas the so called high-affinity uncompetitive antagonists have affinities in the low nanomolar range (Rogawski, 1993).

The objective of the present study was to evaluate the anticonvulsant activity of alkyl and phenyl derivatives of nipecotic acid and benzylamide derivatives of pipecolic acid, by testing their ability (1) to protect mice against MES seizures; (2) to elevate the threshold to electroshock-induced seizures and; (3) to be neurotoxic. It has been suggested that the MES test, with its strong seizure stimulus may result in false negatives and rejection of potential anticonvulsants in early phases of testing. This may be particularly true with GABA-mimetic compounds (Löscher and Schmidt, 1988). The use of the MES test and elevation of threshold test in parallel allows for a comparison of activity. In addition, the calculation of PI values using seizure threshold models may avoid underestimation of anticonvulsant selectivity of test agents (Löscher and Nolting, 1991).

Additional objectives of this study included the assessment of the ability of 2-PC benzylamides to displace [ $^3\text{H}$ ]TCP binding to the PCP site of the NMDA receptor in rat brain, to determine if binding activity correlates with pharmacological activity. Select 2-PC benzylamides were tested for their ability to protect against pentylenetetrazol (PTZ)-, 4-aminopyridine (4-AP)- and NMDA-induced seizures. The low-affinity uncompetitive NMDA antagonist, ADCI, has been shown to provide protection in the MES test and against PTZ-, 4-AP- and NMDA-induced seizures. Finally, select compounds were evaluated in corneal and amygdala kindling for their abilities to reduce seizure severity and alter seizure parameters. Both kindling models have been suggested to be models of human complex partial seizures, in that the pharmacological effectiveness of



1



2



a: X=O; R=CH<sub>2</sub>CH<sub>3</sub>b: X=O; R=(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>c: X=O; R= d: X=NH; R= 

Fig. 1. Parent structures for derivatives of (1) 2-piperidinecarboxylic acid and (2) 3-piperidinecarboxylic acid. Structural modifications of (1) are listed in Table 1.

antiepileptic drugs in corneal kindled rats is very similar to that observed in amygdala kindled rats (Albright and Burnham, 1980; Kupferberg, 1989), although results from this laboratory with novel compounds suggested differences between these two models (Edafiogho *et al.*, 1992; Scott *et al.*, 1993).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.